ADOCIA Reinforces Its Board of Directors with the Appointment of Three New Independent Members
June 01 2021 - 12:00PM
Business Wire
Regulatory News:
ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage
biopharmaceutical company specialized in the development of
innovative formulations of proteins and peptides, announces today
the appointment of three independent Directors to the Board of
Directors. The appointees: Claudia Mitchell, Katherine Bowdish and
Stéphane Boissel joined the board as of May 21, 2021. In parallel,
Dominique Takizawa has decided to resign after ten years of service
on the board.
“We are pleased to welcome three highly talented people at the
time where Adocia is progressing in late-stage development of key
insulin assets while continuing to pioneer new innovative
approaches in cell therapy and obesity”, said Gérard Soula, CEO and
President of the Board of Directors of Adocia. “On behalf of all
board members, I would like to warmly thank Dominique Takizawa for
her engagement and expertise.”
Dr. Claudia Mitchell, Senior VP, Head of Portfolio
Strategy, at Astellas Pharma, has a thorough grounding in the
biotech sector. Prior to joining Astellas in 2019, she co-founded
Universal Cell and served as CEO until Astellas acquired the
company only four years later for over $100 million. She also
co-founded Halo-Bio RNAi Therapeutics and served as Chief
Scientific Officer. Besides being a biotech entrepreneur, Dr.
Mitchell has also worked as a Program Director at the LGMD2I
Research Fund, a family non-profit foundation, and she held a
tenured Academic research position at the French National Institute
of Medical Research (INSERM). Dr. Claudia Mitchell received the
prestigious EY Entrepreneur of the Year award in Life Sciences for
the Pacific Northwest Region, USA. She has a PhD in Molecular
Biology from the University of Paris and an MBA in International
Management from the Ecole des Ponts Business School, Paris,
France.
Dr. Katherine Bowdish, President & CEO of PIC
Therapeutics, is a highly experienced professional in the life
science sector having co-found several companies working on
biological therapies. Beginning in 2013 Dr. Katherine Bowdish
worked with Sanofi for seven years where she established and led
Sanofi Sunrise, a venture investment vehicle, focused on advancing
pioneering science of strategic interest to Sanofi. Following this
she was VP and Head of R&D Strategy at Sanofi. Prior to this,
Dr. Katherine Bowdish was Co-founder, President & CEO of
Anaphore; President of Alexion Antibody Technologies; SVP with
Alexion Pharmaceuticals; and founder, CEO & Chief Scientific
Officer at Prolifaron, prior to its acquisition by Alexion. Dr.
Katherine Bowdish holds a Ph.D. in molecular genetics from Columbia
University College of Physicians and Surgeons in New York City, and
a B.S. degree in biology from the College of William and Mary in
Virginia, USA.
Stéphane Boissel, Chairman and CEO of SparingVision, is a
seasoned biotech professional with over twenty-five years of
leadership experience across corporate finance strategy and
business development in internationally focused companies.
Previously, Stéphane Boissel was Executive Vice President of
Corporate Strategy at Sangamo Therapeutics. Before this he was CEO
at TxCell, a CAR-Treg company that was acquired under his watch.
Stéphane Boissel studied management and finance at the University
of Lyon and Paris-Dauphine in France and received his MBA from the
University of Chicago (IL, USA).
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring five clinical-stage products and several
pre-clinical products. The proprietary BioChaperone® technological
platform is designed to enhance the effectiveness and/or safety of
therapeutic proteins while making them easier for patients to use.
Adocia customizes BioChaperone to each protein for a given
application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: two combinations of rapid acting insulin
analogs and Pramlintide (BioChaperone® Lispro Pram and
BioChaperone® Aspart Pram), a combination of insulin glargine with
GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In
addition, there are two bi-hormonal products for the treatment of
obesity: a combination of glucagon and exenatide (BioChaperone®
Glucagon Exenatide) and a combination of pramlintide and exenatide
(PramExe).
Adocia recently added a preclinical program to its pipeline with
a cell therapy initiative focused on development of a hydrogel
scaffold for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 20, 2021
(a copy of which is available at www.adocia.com) and to the
development of economic conditions financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Adocia to be
materially different from such forward-looking statements. This
press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210601005787/en/
Adocia Adocia Gérard Soula CEO
contactinvestisseurs@adocia.com Ph: +33 4 72 610 610
www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu Ph: +49 89 210
228 0
The Ruth Group Adocia Investor Relations USA James
Salierno Vice-President jsalierno@theruthgroup.com Ph.: +1 646
536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024